miércoles, 2 de febrero de 2022

COVID-19: subcutaneous casirivimab and imdevimab reduce symptomatic disease risk in PCR-positive people

COVID-19: subcutaneous casirivimab and imdevimab reduce symptomatic disease risk in PCR-positive people

No hay comentarios:

Publicar un comentario